Is GlaxoSmithKline PLC getting ready to take off?

April 16, 2021 07:05 PM AEST | By Team Kalkine Media
Follow us on Google News:

Source: Poring Studio, Shutterstock


  • GlaxoSmithKline PLC (LON: GSK) gained 4.56% percent in the last trading session.
  • The stock soared almost ~16.64 percent in the last eight weeks, the price has broken out of its falling channel pattern.
  • GSK’s prices are trading above a horizontal trend line support on the daily chart and getting support from the 50-period SMA.
  • GSK stock prices are trading in a falling wedge formation on the weekly chart and the MACD generated a fresh positive crossover signal.

GlaxoSmithKline PLC (LON: GSK) share price has witnessed a sharp recovery from the low of GBX 1,190.80 made on 26 February 2021 to the recent high of GBX 1,389 tested on 15 April 2021, a gain of ~16.64 percent in the last eight weeks. On Thursday, the stock prices closed at GBX 1,348.40 level, up by  4.56%, and remained as one of the top gainers in the FTSE 100 index. The stock outperformed some of its peers, such as AstraZeneca Plc. (LON: AZN) up 1.77%, and Faron Pharmaceuticals Oy. (LON: FARN) up 1.47%.

GSK stock price breaks out of a falling channel pattern on the daily chart

Source: Refinitiv, Thomson Reuters; Analysis: Kalkine Group

The stock has broken out its descending channel pattern at GBX 1,320 level on 16 April 2021 on the daily chart. After consolidating for more than 11 months in a channel pattern, the price registered a decisive breakout that suggests a change in the trend from sideways to upward. The Stock has also broken a horizontal trendline resistance level (black color horizontal line in the above chart) at GBX 1,322.18 level. The volume has also gone up in the last trading session, which indicates higher participation.

Besides, the price is trading above its 50-period SMA, acting as a crucial support zone below the upper band of the channel pattern. The momentum oscillator RSI (14-period) is trading at ~65 levels, indicating a positive trend for the stock. MACD is also showing a positive crossover and trading above the centerline further indicates an upside direction for the stock. The Parabolic SAR indicator is trading above the current market prices and acting as a short-term resistance zone for stock.

GSK on a weekly chart

Source: Refinitiv, Thomson Reuters; Analysis: Kalkine Group

The stock prices are trading in a falling wedge pattern for the last one year and currently, prices are approaching the upper band of the pattern. The price has fallen almost ~40 percent from its high of GBX 1,669.80 made on 20 July 2020 to the low of a GBX 1,190.80 made on 26 February 2021.

The stock price is well placed below its 50-period SMA, acting as the important resistance at the upper end. However, the momentum oscillator RSI (14-period) is trading at ~50 levels, indicating a possibility of further upside movement in the stock towards the resistance zone. The prices are trading above the Parabolic SAR indicator, acting as an immediate support zone for the stock near the lower band of the wedge pattern. Recently MACD was showing a positive crossover indicating that the bulls are back in action. The major resistance level for the stock is at GBX 1,410.70 level.

Based on the above chart analysis and technical outlook, the GlaxoSmithKline PLC. price seems to be in the recovery phase. Currently, the stock prices are approaching the key resistance zone. The chart pattern suggests that there might be more action expected in GSK if the price breaks the important resistance levels in the coming weeks.


The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

Top ASX Listed Companies

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK